Skip to main content

From the Literature

From the Literature, Gastrointestinal Cancers, Checkpoint Inhibitors

First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Lymphoma, CAR T-Cell Therapy

Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Breast Cancer, Checkpoint Inhibitors

Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature

Daily Aspirin Does Not Lower Colorectal Cancer Risk When Started After Age 70

From the Literature

Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer

From the Literature

New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists in America

From the Literature, Breast Cancer, Dose Escalation/Reduction

Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Bladder Cancer

Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Leukemia

Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Colorectal Cancer, Biomarkers

Pembrolizumab Shows Long-Term Benefits in Patients with Metastatic Colorectal Cancer and MSI-H or dMMR

1
2
3
4

Page 1 of 4
Results 1 - 10 of 38